The Beauty Health Company (NASDAQ:SKIN) Receives Average Rating of "Hold" from Analysts

Shares of The Beauty Health Company (NASDAQ:SKIN - Get Free Report) have earned a consensus rating of "Hold" from the six brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $2.8125.

Several equities analysts have recently commented on the stock. Roth Capital assumed coverage on shares of Beauty Health in a report on Friday, September 19th. They issued a "buy" rating and a $3.50 target price on the stock. TD Cowen boosted their target price on shares of Beauty Health from $2.00 to $2.50 and gave the stock a "hold" rating in a report on Monday, September 22nd. Cowen reissued a "hold" rating on shares of Beauty Health in a report on Monday, September 22nd. Wall Street Zen raised shares of Beauty Health from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Stifel Nicolaus upped their price target on shares of Beauty Health from $3.00 to $4.00 and gave the company a "hold" rating in a research note on Friday, August 1st.

Beauty Health Stock Performance

SKIN opened at $1.43 on Friday. The firm has a market cap of $181.35 million, a P/E ratio of -5.11 and a beta of 1.21. Beauty Health has a 1-year low of $0.78 and a 1-year high of $2.69. The company has a 50 day simple moving average of $2.03 and a two-hundred day simple moving average of $1.70. The company has a debt-to-equity ratio of 4.91, a current ratio of 5.15 and a quick ratio of 4.15.

Beauty Health (NASDAQ:SKIN - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.09. Beauty Health had a negative net margin of 6.13% and a negative return on equity of 32.82%. The business had revenue of $78.20 million during the quarter, compared to analyst estimates of $74.67 million. Beauty Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts forecast that Beauty Health will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Beauty Health

A number of hedge funds have recently bought and sold shares of the business. Soleus Capital Management L.P. purchased a new stake in Beauty Health during the second quarter valued at $1,910,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Beauty Health by 40.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,570 shares of the company's stock valued at $120,000 after purchasing an additional 18,128 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Beauty Health by 33.5% during the second quarter. The Manufacturers Life Insurance Company now owns 41,488 shares of the company's stock valued at $79,000 after purchasing an additional 10,410 shares in the last quarter. Mirabella Financial Services LLP raised its stake in Beauty Health by 5.0% during the second quarter. Mirabella Financial Services LLP now owns 12,861,549 shares of the company's stock valued at $24,566,000 after purchasing an additional 614,602 shares in the last quarter. Finally, Invesco Ltd. raised its stake in Beauty Health by 6.6% during the second quarter. Invesco Ltd. now owns 98,427 shares of the company's stock valued at $188,000 after purchasing an additional 6,059 shares in the last quarter. Hedge funds and other institutional investors own 93.26% of the company's stock.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.